Levodopa-induced dyskinesia in Parkinson disease (original) (raw)
Profile of levodopa-induced dyskinesia in patients of Parkinson’s disease: a record based study
Pritikanta PAUL
Neurological Research, 2014
View PDFchevron_right
Levodopa-dyskinesia incidence by age of Parkinson's disease onset
Neeraj Kumar
Movement Disorders, 2005
View PDFchevron_right
Levodopa-induced dyskinesia in Parkinson’s disease: still no proof? A meta-analysis
Maria Chondrogiorgi
Journal of Neural Transmission, 2018
View PDFchevron_right
Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
Reeja Rajan
Annals of Indian Academy of Neurology, 2019
View PDFchevron_right
Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease
Rafael González Redondo
Parkinson's disease, 2012
View PDFchevron_right
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
Nicola Tambasco
Parkinson's Disease, 2012
View PDFchevron_right
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Akash Roy
Postgraduate Medical Journal, 2007
View PDFchevron_right
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Nicola Tambasco, Veronica Ghiglieri
The Lancet Neurology, 2010
View PDFchevron_right
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease
Georgios Tagaris
Movement Disorders, 2010
View PDFchevron_right
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
Aristide Merola
Annals of Neurology
View PDFchevron_right
The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson’s disease
Olivier Rascol
Journal of Neurology, 2000
View PDFchevron_right
Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible?
Roberto Marconi
Annals of Neurology, 2000
View PDFchevron_right
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
John Maldonado
Movement Disorders, 2005
View PDFchevron_right
The acute brain response to levodopa heralds dyskinesias in Parkinson disease
James Rowe, Damian Herz
Annals of neurology, 2014
View PDFchevron_right
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease
Joao Siffert
Movement Disorders, 2017
View PDFchevron_right
Central Levodopa Influx and the Clinical Motor Response to Levodopa in Patients With Parkinson Disease Complicated With Motor Fluctuations and Dyskinesias
María De Ceballos
Clinical Neuropharmacology, 2009
View PDFchevron_right
A REVIEW: PARKINSON'S DISEASE
Yogeshwary Bhongade
View PDFchevron_right
The Levodopa Response Varies in Pathologically Confirmed Parkinson's Disease: A Systematic Review
Donald Grosset
Movement Disorders Clinical Practice, 2020
View PDFchevron_right
Levodopa responsiveness in disorders with parkinsonism: A review of the literature
Radu Ionut Constantinescu
Movement Disorders, 2007
View PDFchevron_right
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
Mark Stacy
Movement Disorders, 2013
View PDFchevron_right
Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with 6-Month Followup
Gianni Pezzoli
Parkinson's Disease, 2012
View PDFchevron_right
Intrajejunal levodopa Infusion in advanced Parkinson’s disease: long-term effects on motor and non-motor symptoms and impact on patient’s and caregiver’s quality of life. Eur Rev Med Pharmacol Sci
Anna Rita Bentivoglio
European review for medical and pharmacological sciences
View PDFchevron_right
Levodopa in the treatment of Parkinson's disease: an old drug still going strong
Angelo Antonini
2010
View PDFchevron_right
The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications
Jelena Marinković
European Journal of Neurology, 2002
View PDFchevron_right
Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease
Sarah Culgin
Brain Research Bulletin, 2007
View PDFchevron_right
Side effects induced by the acute levodopa challenge in Parkinson’s Disease and atypical parkinsonisms
Loredana Raciti
PLOS ONE
View PDFchevron_right
Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
Ligia Bancu
Brain Sciences, 2021
View PDFchevron_right
Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment
Jacob Sage
Movement Disorders, 2004
View PDFchevron_right
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease
Miguel Valencia
Brain, 2006
View PDFchevron_right
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidenceof dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491
Olivier Rascol
New England Journal of Medicine
View PDFchevron_right
Evaluation of the Efficacy of Pramipexole for Treating Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
Masahiko Suzuki
Internal Medicine, 2013
View PDFchevron_right
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease
Mark Stacy
CNS Drugs, 2007
View PDFchevron_right
Differential progression of motor impairment in levodopa-treated Parkinson's disease
Glenn Stebbins
Movement Disorders, 2000
View PDFchevron_right
Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment
Narongrit Kasemsap
Neuropsychiatric Disease and Treatment, 2016
View PDFchevron_right